Étiquette : endocannabinoïdes

The cannabinoids : An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection, R. Mechoulam & L. Hanus, 2001

The cannabinoids : An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection R. Mechoulam PhD, L Hanušs PhD Pain Research Management, 2001, 6, (2), 67-73. Doi : 10.1155/2001/183057   The present paper describes the historical use of cannabis, starting with its use in Assyria and China. Recent advances in the understanding of the molecular basis of cannabis action are explained, including the identification of the cannabinoid receptors CB1 and CB2, as well as the isolation of endogenous cannabinoids from the brain and periphery. The use of delta9-tetrahydrocannabinol as an antivomiting and antinausea drug for cancer [...]

Lire la suite

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial, Berzenn Urbi et al., 2019,

Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease progression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial Berzenn Urbi, Simon Broadley, Richard Bedlack, Ethan Russo, Arman Sabet British Medical Journal Open, 2019, 9, e029449. doi : 10.1136/bmjopen-2019-029449   Abstract Introduction : Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3–5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy [...]

Lire la suite

Endocannabinoid System, Aleksandra Tarasiuka et al., 2019

Endocannabinoid System Aleksandra Tarasiuka, Maciej Salagaa, and Jakub Fichna Encyclopedia of Gastroenterology, 2nd Edition, 2019 © 2019 Elsevier Inc. All rights reserved. https://doi.org/10.1016/B978-0-12-801238-3.65635-0 1   Introduction 1 Cannabinoids and Their Role in the Physiological and Pathophysiological Processes in the GI Tract 3 Physiological Conditions 3 Gut motility 3 Gastric secretion and emptying 3 Pathophysiological Conditions 4 IBS 4 IBD 5 Colon cancer 5 Peptic ulcer disease 5 Endocannabinoid System and Its Interplay With Other Systems 5 Cholecystokinin 5 Endovanilloids 6 Opioids 6 Endocannabinoid System and Gut Microbiota 6 Conclusion 7 Acknowledgments 7 References Introduction Endocannabinoid system (ECS) is one of the crucial physiological systems that may be targeted to improve human health. Endocannabinoids and their receptors are localized in various organs (heart, lungs, urinary bladder, [...]

Lire la suite

Endocannabinoid-mediated synaptic plasticity and substance use disorders, E. Fernandez-Espejo & L. Nunez-Dominguez, 2019

Endocannabinoid-mediated synaptic plasticity and substance use disorders E. Fernandez-Espejo, L. Nunez-Dominguez Neurologia, 2019 Copyright © 2019 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved. doi : 10.1016/j.nrl.2018.12.004 Abstract Drugs impact brain reward circuits, causing dependence and addiction, in a condition currently described as substance use disorders. Mechanisms of synaptic plasticity in these circuits are crucial in the development of addictive behaviour, and endocannabinoids, particularly anandamide and 2-arachidonyl-glycerol, participate in normal neuroplasticity. Substance use disorders are known to be associated with disruption of endocannabinoid-mediated synaptic plasticity, among other phenomena. Endocannabinoids mediate neuroplasticity in the short and the long term. In the short term, [...]

Lire la suite

Cannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System, Patrícia Schonhofen et al., 2018

Cannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System Patrícia Schonhofen, Ivi Juliana Bristot, José Alexandre Crippa, Jaime Eduardo Cecílio Hallak, Antônio Waldo Zuardi, Richard B. Parsons, Fábio Klamt CNS Drugs, 2018, 32, (Suppl 1), 1-16. Springer Nature Switzerland, Doi : 10.1007/s40263-018-0550-4 Abstract The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components—cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes—are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor [...]

Lire la suite

Effects of endocannabinoid neurotransmission modulators on brain stimulation reward, Styliani Vlachou et al., 2006

Effects of endocannabinoid neurotransmission modulators on brain stimulation reward Styliani Vlachou, George G. Nomikos & George Panagis Psychopharmacology, 2006, 188, 293–305 Doi : 10.1007/s00213-006-0506-0   Abstract Rationale : The endogenous cannabinoid system is responsive to the neurobiological actions of Δ9-tetrahydrocannabinol (THC) and other cannabinoid ligands. While numerous studies have focused on the behavioral and pharmacological effects of THC and cannabinoid agonists in experimental animals, most recent work focuses on compounds that modulate endocannabinoid neurotransmission. However, the relevant studies concerning the ability of endocannabinoid modulators to modify reward processes in experimental animals remain rather scarce. Objectives : The present study examined the effects of drugs modulating endocannabinoid neurotransmission on [...]

Lire la suite

Endocannabinoid system in sexual motivational processes : Is it a novel therapeutic horizon ?, Renata Androvicova et al., 2017

Endocannabinoid system in sexual motivational processes : Is it a novel therapeutic horizon ? Renata Androvicova, Jiri Horacek, Tibor Stark, Filippo Drago, Vincenzo Micale Pharmacological Research, 2017, 115, 200–208 http://dx.doi.org/10.1016/j.phrs.2016.11.021   a b s t r a c t The endocannabinoid system (ECS), which is composed of the cannabinoid receptors types 1 and 2 (CB1 and CB2) for marijuana’s psychoactive ingredient 9-tetrahydrocannabinol (9-THC), the endogenous ligands (AEA and 2-AG) and the enzymatic systems involved in their biosynthesis and degradation, recently emerged as important modulator of emotional and non-emotional behaviors. For centuries, in addition to its recreational actions, several contradictory claims regarding the effects of Cannabis use in sexual functioning and behavior [...]

Lire la suite

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia, M. Fakhoury, 2017

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia M. Fakhoury Molecular Neurobiology, 2017, 54, (1), 768-778. doi: 10.1007/s12035-016-9697-5   ABSTRACT : The endocannabinoid system (ECS) is a group of neuromodulatory lipids, enzymes, and receptors involved in numerous behavioral and physiological processes such as mood, memory, and appetite. Recently, longitudinal and postmortem studies have shown that the ECS might be involved in neuropsychiatric disorders like schizophrenia. However, despite the large amount of research, our knowledge of the ECS and its implication in this debilitating disorder is still largely limited. This review aims at providing a comprehensive overview of the current state of knowledge of the [...]

Lire la suite

Cannabinoids and Schizophrenia : Risks and Therapeutic Potential, Marc W. Manseau & Donald C. Goff, 2015

Cannabinoids and Schizophrenia : Risks and Therapeutic Potential Marc W. Manseau & Donald C. Goff Neurotherapeutics, 2015, 12, 816–824 DOI 10.1007/s13311-015-0382-6 # The American Society for Experimental NeuroTherapeutics, Inc. 2015   Abstract A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a [...]

Lire la suite

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry, Gioacchino Calapai et al., 2019

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry Gioacchino Calapai, Carmen Mannucci, Ioanna Chinou, Luigi Cardia, Fabrizio Calapai, Emanuela Elisa Sorbara, Bernardo Firenzuoli, Valdo Ricca, Gian Franco Gensini and Fabio Firenzuoli Hindawi - Evidence-Based Complementary and Alternative Medicine, 2019, Article ID 2509129, 11 pages https://doi.org/10.1155/2019/2509129   Background : Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. Objective. &e aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD [...]

Lire la suite